Cargando…

Long-Term Safety of Mometasone Furoate/Formoterol Combination for Treatment of Patients with Persistent Asthma

Objective: The combination of inhaled corticosteroid (ICS) and long-acting β(2)-agonist is recommended for treatment of patients with persistent asthma inadequately controlled on ICS monotherapy. This study was conducted to evaluate the long-term safety of mometasone furoate/formoterol (MF/F) admini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maspero, Jorge F, Nolte, Hendrik, Chérrez-Ojeda, Iván
Formato:	Texto
Lenguaje:	English
Publicado:	Informa Healthcare 2010
Materias:	Asthma Treatment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2993043/ https://www.ncbi.nlm.nih.gov/pubmed/20874458 http://dx.doi.org/10.3109/02770903.2010.514634

Ejemplares similares

Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma
por: Bernstein, David I, et al.
Publicado: (2011)

Effect of mometasone furoate/formoterol combination therapy on nocturnal awakenings in subjects with persistent asthma
por: Pearlman, David, et al.
Publicado: (2011)

191 Quality of Life Improvements in Persistent Asthma Subjects Receiving Combined Mometasone Furoate and Formoterol
por: Murphy, Kevin, et al.
Publicado: (2012)

190 Effect of Mometasone Furoate/Formoterol Combination Therapy on Nocturnal Awakenings in Subjects With Persistent Asthma
por: Pearlman, David, et al.
Publicado: (2012)

Efficacy and safety of combined medium-dose mometasone furoate/formoterol (MF/F) in persistent asthmatics
por: Nathan, Robert A, et al.
Publicado: (2010)

189 Efficacy and Safety of Two Doses of Mometasone Furoate/Formoterol Combination Treatment in Subjects With Severe Asthma
por: Weinstein, Steven, et al.
Publicado: (2012)

Efficacy and safety of medium and high doses of mometasone furoate/formoterol (MF/F) combination treatment in subjects with severe persistent asthma
por: Weinstein, Steven F, et al.
Publicado: (2010)

Asthma control using a combination of mometasone furoate/formoterol: grouped analysis of three clinical trials
por: White, Martha, et al.
Publicado: (2011)

Non-inferiority efficacy comparison of mometasone furoate/formoterol versus fluticasone propionate/salmeterol combination therapies in subjects with persistent asthma
por: Bernstein, David I, et al.
Publicado: (2010)

188 Efficacy Comparison of Mometasone Furoate/Formoterol Versus Fluticasone Propionate/Salmeterol Combination Therapies in Subjects With Persistent Asthma: Noninferiority and Onset-of-Action Findings
por: Bernstein, David, et al.
Publicado: (2012)

One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies
por: Chapman, Kenneth, et al.
Publicado: (2021)

Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction
por: Lazarinis, Nikolaos, et al.
Publicado: (2014)

192 Efficacy and Safety of Combined Mometasone Furoate/Formoterol 100/10ìG Twice Daily in Subjects with Asthma Inadequately Controlled on Low-Dose Inhaled Corticosteroids
por: Meltzer, Eli, et al.
Publicado: (2012)

Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone
por: Bateman, Eric D, et al.
Publicado: (2014)

Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β(2) agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomised trial
por: Busse, William W, et al.
Publicado: (2013)

Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population
por: Sagara, Hironori, et al.
Publicado: (2021)

Special Features of Asthma in Children
por: Cropp, Gerd J.A.
Publicado: (1985)

187 Reduction in Asthma Deteriorations in Subjects with Persistent Asthma not Well Controlled on Low-, Medium-, or High-Dose Inhaled Corticosteroids: A Pooled Analysis From Three Clinical Trials Using Combined Mometasone Furoate/Formoterol
por: Weinstein, Steven, et al.
Publicado: (2012)

Efficacy of mometasone furoate and fluticasone furoate on persistent allergic rhinoconjunctivitis
por: Aneeza, W. Hamizan, et al.
Publicado: (2013)

Reduction in asthma deteriorations in subjects with persistent asthma uncontrolled on low-, medium-, or high-dose inhaled corticosteroids: a pooled analysis from three clinical trials using combined mometasone furoate/formoterol
por: Weinstein, SF, et al.
Publicado: (2011)

Mometasone furoate/formoterol combination therapy increases frequency of days/nights free of short-acting β(2)-agonist use
por: Nayak, AS, et al.
Publicado: (2011)

Asthma control with ICS-formoterol reliever versus maintenance ICS and SABA reliever therapy: a post hoc analysis of two randomised controlled trials
por: Hatter, Lee, et al.
Publicado: (2022)

Mometasone furoate in the management of asthma: a review
por: Tan, Ricardo A, et al.
Publicado: (2008)

Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease
por: Kosoglou, Teddy, et al.
Publicado: (2013)

Long-term safety of Mometasone Furoate administered via a dry powder inhaler in children: Results of an open-label study comparing Mometasone Furoate with Beclomethasone Dipropionate in children with persistent asthma
por: Noonan, Michael, et al.
Publicado: (2009)

Disadvantage in early-life and persistent asthma in adolescents: a UK cohort study
por: Creese, Hanna, et al.
Publicado: (2022)

Persistent variations in national asthma mortality, hospital admissions and prevalence by socioeconomic status and region in England
por: Gupta, Ramyani P, et al.
Publicado: (2018)

Economic analysis of temperature-controlled laminar airflow (TLA) for the treatment of patients with severe persistent allergic asthma
por: Brazier, Peter, et al.
Publicado: (2016)

Cases Which May Benefit from Surgical Measures
Publicado: (1919)

Managing moderate-to-severe paediatric asthma: a scoping review of the efficacy and safety of fluticasone propionate/salmeterol
por: Pitrez, Paulo Marcio, et al.
Publicado: (2023)

Efficacy and Safety Evaluation of Mometasone Furoate in Treating Ocular Inflammation
por: Lage, Nayara Almeida, et al.
Publicado: (2023)

Description of the protocol for the PRACTICAL study: a randomised controlled trial of the efficacy and safety of ICS/LABA reliever therapy in asthma
por: Fingleton, James, et al.
Publicado: (2017)

Phenotypic characteristics and asthma severity in an East African cohort of adults and adolescents with asthma: findings from the African severe asthma project
por: Kirenga, Bruce, et al.
Publicado: (2020)

Lung Function Normalisation with Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Asthma
por: Chapman, Kenneth R., et al.
Publicado: (2021)

Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era
por: Jackson, David J, et al.
Publicado: (2021)

Development of a conceptual model of childhood asthma to inform asthma prevention policies
por: Adibi, Amin, et al.
Publicado: (2021)

Economic burden of asthma in Singapore
por: Finkelstein, Eric A, et al.
Publicado: (2021)

Seasonal variability of lung function and Asthma Quality of Life Questionnaire Scores in adults with uncontrolled asthma
por: Bauer, Rebecca N, et al.
Publicado: (2019)

Asthma exacerbation prevalence during the COVID-19 lockdown in a moderate-severe asthma cohort
por: de Boer, Geertje, et al.
Publicado: (2021)

Asthma control is associated with economic outcomes, work productivity and health-related quality of life in patients with asthma
por: Lee, Lulu K, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sn99nij4q43vct9mcidvcg3n78